Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ABCG2 | Q9UNQ0 | 6/20 | 0.78 |
| ▸ | PDE4A | P27815 | 1/20 | 0.69 |
| ▸ | PDE4B | Q07343 | 1/20 | 0.69 |
| ▸ | PDE4C | Q08493 | 1/20 | 0.69 |
| ▸ | PDE4D | Q08499 | 1/20 | 0.69 |
| ▸ | MAPT | P10636 | 2/20 | 0.61 |
| ▸ | TNFRSF1A | P19438 | 1/20 | 0.61 |
| ▸ | APP | P05067 | 2/20 | 0.60 |
| ▸ | XDH | P47989 | 1/20 | 0.57 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1425360 | 1.00 | ABCG2 (0.78) | ABCG2PDE4APDE4BPDE4CPDE4D | |
| SCHEMBL1425240 | 0.90 | ABCG2 (0.78) | ABCG2PDE4APDE4BPDE4CPDE4D | |
| SCHEMBL1425245 | 0.90 | ABCG2 (0.78) | ABCG2PDE4APDE4BPDE4CPDE4D | |
| SCHEMBL4851201 | 0.87 | ABCG2 (0.73) | ABCG2PDE4APDE4BPDE4CPDE4D | |
| SCHEMBL4845554 | 0.87 | ABCG2 (0.73) | ABCG2PDE4APDE4BPDE4CPDE4D | |
| SCHEMBL633046 | 0.87 | ABCG2 (0.97) | ABCG2PDE4APDE4BPDE4CPDE4D | |
| SCHEMBL633045 | 0.87 | ABCG2 (0.97) | ABCG2PDE4APDE4BPDE4CPDE4D | |
| SCHEMBL1425154 | 0.84 | TUBB1 (0.61) | ABCG2MAPTTNFRSF1AAPPXDH | |
| SCHEMBL1425149 | 0.84 | TUBB1 (0.61) | ABCG2MAPTTNFRSF1AAPPXDH | |
| SCHEMBL6907516 | 0.83 | ABCG2 (0.89) | ABCG2PDE4APDE4BPDE4CPDE4D |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1432669-B1 | 4-(C2-6 ALKOXY)-SUBSTITUTED CHALCONES AS THERAPEUTIC AGENTS | SPEAR THERAPEUTICS LTD (GB) | 2011-03-23 | — | — | EP | disclosed |
| US-7112698-B2 | 4-(c2-6alkoxy)-substituted chalcones as therapeutic agents | SPEAR THERAPEUTICS LIMITED (GB) | 2006-09-26 | — | — | US | disclosed |
| US-20040259957-A1 | 4-(c2-6alkoxy)-substituted chalcones as therapeutic agents | SPEAR THERAPEUTICS LIMITED (GB) | 2004-12-23 | — | — | US | disclosed |
| EP-1432669-A1 | 4-(C2-6 ALKOXY)-SUBSTITUTED CHALCONES AS THERAPEUTIC AGENTS | Cancer Research Technology Limited (GB) | 2004-06-30 | — | — | EP | disclosed |
| WO-2003029176-A1 | 4-(C2-6ALKOXY)-SUBSTITUTED CHALCONES AS THERAPEUTIC AGENTS | CANCER RESEARCH TECHNOLOGY LIMITED (GB) | 2003-04-10 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040259957-A1 | 4-(c2-6alkoxy)-substituted chalcones as therapeutic agents | OXER1, ALK, BCL6 | ABCG2 191/4885PDE4A 3440/4885PDE4B 2870/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.